## Edgar Filing: SOPHIRIS BIO INC. - Form 4

Form 4								
Check this box if no longer STATE	<b>4</b> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							PROVAL 3235-0287 January 31, 2005
Subject to Section 16. Form 4 or Form 5 Filed pu obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						Estimated a burden hour response	•
<ul><li>(Print or Type Responses)</li><li>1. Name and Address of Reporting Slover Peter T</li></ul>	r Name <b>and</b> Ticker or Trading RIS BIO INC. [SPHS]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) ( C/O SOPHIRIS BIO INC., 1 PROSPECT STREET	(Month/D	-	ansaction			Director X Officer (give below)	10%	Owner r (specify
(Street) LA JOLLA, CA 92037	ndment, Date Original nth/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> <li>Person</li> </ul>				
(City) (State)	(Zip) Tabl	le I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	y Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	te 2A. Deemed	3. Transactio Code (Instr. 8) Code V	4. Securit on(A) or Di (Instr. 3,	ties Ad sposed 4 and (A) or	cquired d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of
Common 08/20/2013 Stock		P	4,680	A	\$ 4.245 (1)	4,680	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orfNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	Amor Unde Secur	le and unt of rlying rities : 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: SOPHIRIS BIO INC. - Form 4

## **Reporting Owners**

Reporting Owner Name / Addr	Relationships							
	Director	10% Owner	Officer	Other				
Slover Peter T C/O SOPHIRIS BIO INC. 1258 PROSPECT STREET LA JOLLA, CA 92037	,		Chief Financial Officer					
Signatures								
/s/ Peter T. Slover	08/20/2013							
<u>**</u> Signature of Reporting Person	Date							

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The weighted average sales price for the transaction reported was 4.245, and the range of prices were between 4.22 and 4.25. Upon (1) report the SEC staff, the issuer or any associate for a solution of the same provide a solution of the same
- (1) request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.